Literature DB >> 22009541

[Vagal stimulation - a new possibility for conservative treatment of peripheral arterial occlusion disease].

T Payrits1, A Ernst, E Ladits, H Pokorny, I Viragos, F Längle.   

Abstract

BACKGROUND: The options for the conservative therapy of PAD, and also the achievable benefits are well documented in the S3-guidelines and the TASC-II guidelines. Upon vagal stimulation with a P-STIM device a significant extension of the pain-free and maximum walking distance could be noticed. As this fact continued beyond the end of the therapy, we may have found a new, conservative therapy option to manage PAD. PATIENTS AND METHODS: In a prospective single centre study we reviewed 31  patients with PAD (Fontaine stages  II and III) who were treated by vagal stimulation with a P-STIM device. The following parameters were analysed: indication, duration of therapy, improvement of pain-free walking distance after therapy and complications.
RESULTS: 31  patients received a vagal stimulation therapy for intermittent claudication in Fontaine stages  II (97 %) and III (3 %). The duration of treatment averaged 6  weeks (minimum 2 weeks, maximum 9  weeks). 27 out of 30  patients were able to increase their pain-free walking distance up to a hundred-fold of the initial values. 3  patients could not give any information about increasing their walking distance in meters, but they reported about an obvious amelioration. All patients reported a continuing improvement after 4  weeks and after further 12  weeks, partly even about additional enhancement. Just 1  patient could not improve his walking-distance -after 3  periods of therapy. This was the only -patient with an isolated diabetic microangiopathy without stenosis or occlusions in the large vessels.
CONCLUSION: The considerable increase in pain-free walking distance after vagal stimulation therapy by P-STIM is appreciably better than those which were described for supervised exercise therapy or pharmacotherapy with Naftidrofuryl or Cilostazol. On the basis of these results we think that vagal stimulation by P-STIM might be a new option for treating intermittent claudication. © Georg Thieme Verlag KG Stuttgart ˙ New York.

Entities:  

Mesh:

Year:  2011        PMID: 22009541     DOI: 10.1055/s-0031-1283739

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  5 in total

1.  Numerical modeling of percutaneous auricular vagus nerve stimulation: a realistic 3D model to evaluate sensitivity of neural activation to electrode position.

Authors:  Amine M Samoudi; Stefan Kampusch; Emmeric Tanghe; Jozsef C Széles; Luc Martens; Eugenijus Kaniusas; Wout Joseph
Journal:  Med Biol Eng Comput       Date:  2017-02-13       Impact factor: 2.602

2.  Muscle Decline in Aging and Neuromuscular Disorders - Mechanisms and Countermeasures: Terme Euganee, Padova (Italy), April 13-16, 2016.

Authors: 
Journal:  Eur J Transl Myol       Date:  2016-03-31

Review 3.  Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases.

Authors:  Xi He; Ming Zhao; Xueyuan Bi; Lei Sun; Xiaojiang Yu; Mei Zhao; Weijin Zang
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

Review 4.  Current Directions in the Auricular Vagus Nerve Stimulation I - A Physiological Perspective.

Authors:  Eugenijus Kaniusas; Stefan Kampusch; Marc Tittgemeyer; Fivos Panetsos; Raquel Fernandez Gines; Michele Papa; Attila Kiss; Bruno Podesser; Antonino Mario Cassara; Emmeric Tanghe; Amine Mohammed Samoudi; Thomas Tarnaud; Wout Joseph; Vaidotas Marozas; Arunas Lukosevicius; Niko Ištuk; Antonio Šarolić; Sarah Lechner; Wlodzimierz Klonowski; Giedrius Varoneckas; Jozsef Constantin Széles
Journal:  Front Neurosci       Date:  2019-08-09       Impact factor: 4.677

5.  Continuous auricular electroacupuncture can significantly improve heart rate variability and clinical scores in patients with depression: first results from a transcontinental study.

Authors:  Xian Shi; Gerhard Litscher; Huan Wang; Lu Wang; Zengkai Zhao; Daniela Litscher; Jingqiao Tao; Ingrid Gaischek; Zemin Sheng
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-12       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.